Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review
Journal of Oncology Pharmacy Practice
Published online on March 21, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionVenetoclax is a BCL-2 inhibitor, used for both treatment-naive, and relapsed/refractory chronic lymphocytic leukemia (CLL). To mitigate the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up strategy with frequent assessment is ...
IntroductionVenetoclax is a BCL-2 inhibitor, used for both treatment-naive, and relapsed/refractory chronic lymphocytic leukemia (CLL). To mitigate the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up strategy with frequent assessment is ...